- Overview
- Product Parameters
- Product Description
Basic Info.
Model NO.
101028
Format
Cassette
Certificate
ISO 13485
Storage Temperature
4-30°c
Shelf Life
2 Years
OEM&ODM
Available
Transport Package
Cartons
Specification
66*36*56.5cm/2000 Tests/CTN/12.0kg
Trademark
Testsealabs
Origin
Hangzhou, China
Production Capacity
10000pieces/Day
Product Description
| Format | Cassette | Package | Cartons |
| Specimen | S/P | Certificate | ISO 13485 |
| Storage Temperature | 4-30°C | Pack | 40T |
| Test Time | 15 min | Shelf life | 2 years |
| Sensitivity | >92% | OEM&ODM | Available |
Intended Use
Medical Diagnostic Rapid Test Kit One Step HAV Test Device Cassette is a rapid visual immunoassay for the qualitative presumptive detection of antibodies to HAV in human serum or plasma specimens. This kit is intended to be used as an aid in the diagnosis of HAV infection.
Introduction
HAV is a positive RNA virus, a unique member of picornavirdae. Its transmission depend sprimarily on serial transmission from person to person by the fecal-oral route. Although hepatitis A is not ordinarily a sexually transmitted disease, the infection rate is high among male homosexuals, as result of oral-anal contact.
The anti-HAV IgG is produced in the early stage of infection, its titer in serum or plasma has been qute high at the onset of HAV IGG can not make a HAV diagnosis unless HVA IGM exist at the same time. The presence of HAV IGG, but no HAV gm is a marker of infected HAV and acquired immunity. The presence of specific HAV IGM in blood samples suggests acute or recent HAV infection. The igm antibody rapidly increases in titer over a period of 4-6weeks post infection, and then declines to non-detectable levels within 3-6 months in most patients.
Summary
Hepatitis A IgM/IgG infectious Disease is an acute, usually self-limiting disease of the liver caused by hepatitis A virus (HAV). HAV is transmitted from person to person, primarily by the facal-oral route. The incidence of hepatitis A is closely related to socioeconomic development, and seroepidemiological studies show that prevalence of anti-HAV antibodies in the general population varies from 15% to close to 100% in different parts of the world.
